Viatris presents late breaking abstract on cenerimod at the 26th asia-pacific league of associations for rheumatology annual congress

Late-breaking oral presentation shows that cenerimod for the treatment of moderate to severe systemic lupus erythematosus (sle) in japanese patients can be considered safe and well-tolerated data shows a clinically meaningful improvement in disease activity consistent with results from other global phase 2 studies of cenerimod pittsburgh , aug. 23, 2024 /prnewswire/ -- viatris inc. (nasdaq: vtrs), a global healthcare company, presented today the results of one of its phase 2 studies* of cenerimod (act-333441). the act-333441 study was accepted as a late-breaking abstract and was presented during an oral presentation at the 26th asia-pacific league of associations for rheumatology (aplar) annual congress.
VTRS Ratings Summary
VTRS Quant Ranking